An observation study of perioperative nintedanib therapy in patients with non-small-cell lung cancer combined with idiopathic pulmonary fibrosis (IPF)

An observation study of perioperative nintedanib therapy in patients with non-small-cell lung cancer combined with idiopathic pulmonary fibrosis (IPF) - Nintedanib therapy in patients with NSCLC with IPF

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039537

Enrollment

Registered

2020-03-01

Start date

2020-05-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small-cell lung cancer combined with idiopathic pulmonary fibrosis (IPF)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-small-cell lung cancer combined with idiopathic pulmonary fibrosis (IPF) Clinical stage I-IIIA Patient who has operative indication

Exclusion criteria

Exclusion criteria: Past history of chest surgery Alternative prior treatment for IPF Past history of chemotherapy or radiation for chest Administration of oxygen therapy Infectious disease requiring treatment

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Postoperative exacerbation-free time of IPF 2-year survival rate	—

Countries

Japan

Contacts

Public ContactNozomu Motono

Kanazawa Medical University Thoracic Surgery

motono@kanazawa-med.ac.jp0762862211

Outcome results